Vaxxinity, Inc. (VAXX)

NASDAQ: VAXX · IEX Real-Time Price · USD
0.718
+0.029 (4.14%)
At close: Mar 28, 2024, 4:00 PM
0.730
+0.012 (1.74%)
After-hours: Mar 28, 2024, 7:41 PM EDT
4.14%
Market Cap 82.38M
Revenue (ttm) n/a
Net Income (ttm) -56.93M
Shares Out 126.75M
EPS (ttm) -0.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 334,324
Open 0.670
Previous Close 0.689
Day's Range 0.670 - 0.730
52-Week Range 0.560 - 3.100
Beta 2.47
Analysts Buy
Price Target 7.00 (+875.61%)
Earnings Date Mar 27, 2024

About VAXX

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 11, 2021
Employees 87
Stock Exchange NASDAQ
Ticker Symbol VAXX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for VAXX stock is "Buy" and the 12-month stock price forecast is $7.0.

Price Target
$7.0
(875.61% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

Presentation will address the Company's clinical data in Parkinson's disease Presentation will address the Company's clinical data in Parkinson's disease

15 hours ago - GlobeNewsWire

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financia...

1 day ago - GlobeNewsWire

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024

UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson's patients UB-312 is first immunotherapy to show reduction of pathological alpha-syn...

21 days ago - GlobeNewsWire

Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys.

6 weeks ago - GlobeNewsWire

Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical ...

6 weeks ago - GlobeNewsWire

Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a research collaboration ...

2 months ago - GlobeNewsWire

Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida

CAPE CANAVERAL, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a collaboration with the...

2 months ago - GlobeNewsWire

Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference

CAPE CANAVERAL, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Ex...

3 months ago - GlobeNewsWire

Vaxxinity to Present at Upcoming November Medical and Investor Conferences

CAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and e...

4 months ago - GlobeNewsWire

Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update

CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the ...

5 months ago - GlobeNewsWire

Vaxxinity to Present at Upcoming Investor Conferences in September

CAPE CANAVERAL, Fla., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Ex...

7 months ago - GlobeNewsWire

Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer's Disease

Phase 2a data published in The Lancet's eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the most advanced active immunotherapy targeting beta-amyloid in the clin...

8 months ago - GlobeNewsWire

Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update

CAPE CANAVERAL, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the ...

8 months ago - GlobeNewsWire

Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director

Appointment adds Dr. Powchik's experience in the development of marketed immunotherapeutics to Vaxxinity's leadership team

8 months ago - GlobeNewsWire

Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update

CAPE CANAVERAL, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial ...

11 months ago - GlobeNewsWire

Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April

Vaxxinity CEO Mei Mei Hu to participate in fireside chat with Sarah Despres, Counselor to the Secretary for Public Health and Science, U.S. Department of Health and Human Services, at World Vaccine Co...

1 year ago - GlobeNewsWire

Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates

CAPE CANAVERAL, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financia...

1 year ago - GlobeNewsWire

Vaxxinity Joins TransCelerate Research and Development Consortium

CAPE CANAVERAL, Fla., March 21, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced today that it...

1 year ago - GlobeNewsWire

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia

CAPE CANAVERAL, Fla., March 20, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that th...

1 year ago - GlobeNewsWire

Vaxxinity to Present at Upcoming March Scientific and Medical Conferences

Vaxxinity to present new preclinical data on anti-tau Alzheimer's vaccine candidate VXX-301 at AD/PD International Conference Vaxxinity to present new preclinical data on anti-tau Alzheimer's vaccine ...

1 year ago - GlobeNewsWire

ICR Hosts Vaxxinity CEO Mei Mei Hu on the Welcome to the Arena Podcast

NEW YORK--(BUSINESS WIRE)-- #IR--ICR, a leading strategic communications and advisory firm, is pleased to announce that Mei Mei Hu, Chief Executive Officer and Co-Founder, Vaxxinity, Inc. (Nasdaq: VAX...

1 year ago - Business Wire

Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida

Appointment of new directors bring diversity, balance and relevant industry expertise to Vaxxinity

1 year ago - GlobeNewsWire

Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612

Vaxxinity's next-generation COVID-19 booster candidate UB-612 achieves primary and key secondary immunogenicity endpoints in a pivotal head-to-head heterologous booster trial against three authorized ...

1 year ago - GlobeNewsWire

Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Phase 1 Part B End-of-Treatment Data Show UB-312 is Well Tolerated and Immunogenic in Parkinson's Disease Patients

1 year ago - GlobeNewsWire

Vaxxinity to Present at Upcoming Investor Conferences in November

DALLAS, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, Chief...

1 year ago - GlobeNewsWire